Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 9, 2025Journal of Clinical OncologyOpen Access

Genomics Define Malignant Transformation in Myeloma Precursor Conditions

View Full Paper
Ask AI
Bookmark
Share

Authors

FMFrancesco MauraMemorial Sloan Kettering Cancer CenterPBP. Leif BergsagelMayo Clinic in ArizonaBZBachisio ZicchedduUniversity of Miami Health System

Discussion

Loading...

Member takes

Overview

This observational analysis identifies genomic features linked to malignant transformation in MGUS and SMM, suggesting refined risk stratification methods.

Key Points

  • Genomic features can distinguish malignant transformation in multiple myeloma precursor conditions.
  • The study involved genomic data from 374 patients, including 277 for training and 97 for validation.
  • Integration of these genomic features with the 2/20/20 model improved predictions of progression to multiple myeloma.
  • Approximately 60% of MGUS cases show no evidence of malignant transformation, indicating distinct risk levels.

Cite This Study

Maura et al. (2025) studied this question.

synapsesocial.com/papers/68e8439a9989581a2fd4e2c0https://doi.org/10.1200/jco-25-01733
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma2024 · 16 citations
  2. 2Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study2009 · 1,145 citations
  3. 3Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma2021 · 49 citations
  4. 4Frontline treatment of follicular lymphoma: what will it take to change current practice?2025 · 6 citations